Abstract 
Introduction
Calcium elicits the activation of complex intracellular signalling cascades and intracellular messengers. Cytosolic-free calcium plays a crucial role in maintaining homeostasis in living organs and tissues, however, the mechanisms that couple membrane receptor activation to calcium signalling, and the pathways of calcium entry into the cytosol, are only in partly understood [1] . The 9-kilodalton cytosolic calcium-binding protein [2] . The full-length cDNA for human CaBP-9k has been cloned using reverse transcription (RT)-PCR. It consists of 600 nucleotides in length, and contains the coding region for 79-amino acid, 57 nucleotides 5Ј-and 159 nucleotides 3Ј-noncoding region and a poly(A) tail [3] . We have shown that the CaBP-9k locus spans approximately 5.5-kb on the X-chromosome, and consists of three exons and four Alu repeats [4] . We have also shown that a sequence of 50 nucleotides downstream from the human CaBP-9k promoter has extensive homology to the oestrogen response element (ORE) of rat CaBP9k , and that the lack of expression of CaBP-9k in the uterus and possibly placenta in humans may be due to a two-nucleotide change within this region [4] .
CaBP-9k has two calcium-binding domains, and belongs to a family of intracellular proteins with a high affinity for calcium
CaBP-9k is expressed in a variety of mammalian tissues, that is, uterus, placenta, intestine, kidney, pituitary gland and bone [5] [6] [7] [8] [9, 10] . However, CaBP-9k alone is not sufficient to mediate 1,25-dihydroxyvitamin D3-mediated increases in intestinal calcium absorption in rats [11] , and in the uterus, CaBP-9k appears to be involved in the regulation of myometrial activity by intracellular calcium [7] . Thus, the physiological role(s) of CaBP-9k is still a question for further study. Recently, we demonstrated that uterine CaBP-9k is responsive to exogenous E2, and may represent a potential biomarker for exposure to environmental oestrogenic chemicals, the so-called 'endocrine disruptors' [12] [13] [14] [15] [16] . In this review, we will summarize current findings related to the molecular mechanism of regulation of in mammals, and introduce research data from recent studies by us and others. [17] [18] [19] . To more precisely define the role of CaBP-9k in active calcium transport, we generated CaBP-9k-null mice. CaBP9k-knockout (KO) mice had a normal phenotype, and did not display any of the abnormalities of VDR-KO mice [20] , which indicated that there is compensatory gene induction in these animals [21] [22] [23] . In addition, CaBP-9k-KO mice were phenotypically normal at birth and survived for at least 1 year [20] [24] . CaBP-9k-null mice expressed higher levels of duodenal TRPV6 mRNA compared to WT mice, and PMCA1b mRNA levels were significantly induced in KO mice at weaning, whereas they remained constant in WT mice [20] . Others have shown that intestinal TRPV6 mRNA levels increase 30-fold at weaning, coincident with the induction of CaBP-9k expression, and that duodenal PMCA1b is induced during pre-weaning [25, 26] . These results suggest that in the absence of CaBP-9k, the absorption of milk calcium may mediated by compensatory induction of TRPV6 and PMCA1b in CaBP-9k-KO mice [20] .
. It is involved in intestinal calcium absorption, and is regulated at the transcriptional and post-transcriptional levels by 1,25-dihydroxyvitamin D3, the hormonal form of vitamin D

Phenotype of CaBP-9k knockout mouse
The mechanism of regulation of active calcium transport in calcium-related disorders, such as hypocalcaemia, rickets and osteomalacia, in vitamin-D-receptor (VDR)-null mice and 1␣-hydoxylasedeficient mice has been examined
CaBP-9k-null mice maintained normal serum calcium concentrations and showed no abnormal symptoms, which suggests that a normal diet supplies sufficient calcium for CaBP-9k-KO mice [20] [20] . Renal TRPV6 and TRPV5 may also compensate for CaBP-9k in renal calcium re-absorption [20] .
In 
Uterine expression and regulation of CaBP-9k
CaBP-9k is expressed mainly in the endometrial stroma and myometrium of the uterus in non-pregnant rats [28, 29] , whereas in pregnant rats, expression is also observed in the epithelium of the uterus [30] . Bovine CaBP-9k is expressed only in the luminal and glandular epithelium of the endometrium, not in the myometrium or in the stromal cells of the endometrium in non-pregnant animals [31] . [32, 34] . It has also been shown that E2 causes the rapid accumulation of CaBP-9k mRNA in the uterus of OVX rats [36] . In oestrogen-primed OVX rats, P4-inhibited oestrogen-induced CaBP-9k expression, and this effect was completely abrogated by co-administration of the progesterone antagonist RU486 [32] . In pregnant rats, it has been shown that P4 down-regulates CaBP-9k expression in the uterus during early pregnancy [37] .
In OVX gilts, E2 treatment induced an increase in CaBP-9k mRNA levels, whereas administration of P4 to OVX pigs decreased CaBP-9k mRNA levels [38] . In contrast, P4 has been shown to have a positive role in the regulation of CaBP-9k expression in the bovine uterus [31] [39] .
In contrast to rats, the expression of uterine CaBP9k is not under strict oestrogen regulation in mice. CaBP-9k is expressed in the mouse uterus, and the level of expression increases during early pregnancy and implantation [40, 41] . CaBP-9k mRNA is expressed in the luminal and glandular endometrial epithelia in the uterus at the time of implantation, and in the luminal, but not in the glandular, epithelia early in pregnancy (day 5 of pregnancy). In oophorectomized adult mice, P4-enhanced CaBP-9k mRNA expression in the uterus, whereas E2 had no effect [40] . CaBP-9k mRNA is expressed at high levels in the uterus of mice at dioestrus and metoestrus, and at basal levels at prooestrus and oestrus [41] [32, 34, 36, 37] . The level of expression of CaBP-9k mRNA fluctuates during the estrous cycle, but exhibits a very different pattern in the uterus of the rat and mouse [41] [9, 36] . In rats, regulation of CaBP-9k is mediated by an ERE located in the first intron [43] . [64, 65] . In gastrointestinal tissue, the GR is highly expressed in the epithelial cells of the duodenum and jejunum, and GCs appear to be essential for cellular differentiation and maintenance of mineral absorption [66] [67] [68] [62] . In the kidney, CaBP-9k localized mainly to the distal tubule, as expected [62] . The GR is mainly expressed in the glomerulus, but it is also present in the distal segments [69, 70] . Thus, although GRs do not appear to localize to the distal tubule, evidence suggests that the distal tubule is the site of renal CaBP-9k homeostasis, and the site of action of DEX in ADX mice [62] . [62] . Sustained DEX administration suppresses duodenal CaBP-9k expression, but has no effect on renal CaBP-9k. DEX was shown to regulate mouse CaBP-9k expression in a tissue-specific manner. DEX inhibited CaBP-9k expression in the duodenum, temporally induced expression in the kidney, and had no effect on expression levels in the uterus. GR-mediated reduction of duodenal CaBP-9k may be involved in negative calcium absorption in GC-induced osteoporosis (GIO), whereas renal CaBP-9k does not appear to be involved [62] .
In summary, we have examined the regulation of CaBP-9k by GCs in the calcium absorbing and reabsorbing organs, that is, duodenum and kidney, and have presented evidence of the potential role of CaBP-9k in these organs
Pituitary expression and regulation of CaBP-9k
Recently, it was shown that CaBP-9k is highly up-regulated by E2 in the somatolactotrope cell line GH3, a pituitary gland tumour cell line [71] . Recently, the expression and regulation of CaBP-9k mRNA and protein in the rat pituitary gland during the estrous cycle was examined [72] [34] . Furthermore, uterine CaBP-9k expression was also dependent on E2 levels [29, 33] and ER [37, 44] . It is of interest that pituitary levels of CaBP-9k mRNA and protein parallel uterine levels, as it suggests that uterine and pituitary CaBP-9k are expressed and regulated in a similar manner during the estrous cycle in rats [72] . Taken together, these results suggest that pituitary levels of CaBP-9k mRNA and protein are tightly regulated during estrous cycle, and that the steroid hormones, E2 and P4, play a role in the regulation of CaBP-9k in the pituitary gland throughout the cycle of the rat [72] .
Rat CaBP-9k contains an imperfect ERE between exon I and intron A, which binds to the ER [36, 43] . We and others have shown that uterine CaBP-9k mRNA and protein are induced by E2 treatment [12, 35, 73] , and that in immature rats, this increase is mediated via the ER-␣ pathway [74] . ER␣ is highly expressed in the anterior pituitary, while the expression level of ER␤ is very low in this tissue [75] . In addition, ERs do not appear to be expressed in the intermediate and posterior lobes of the pituitary gland [76] , which suggests that an ER/ERE-dependent pathway is a key mechanism of E2-dependent regulation of uterine CaBP-9k. In the pituitary gland, sex steroids are known to regulate anterior pituitary functions through both direct and indirect pathways [77, 78] . After treatment with E2 alone, there was a significant increase in pituitary CaBP-9k after 48 hrs, which was sustained for 72 hrs after the final administration of E2 [72] . CaBP-9k expression has been shown to increase as early as 3 hrs following E2-induction, and peak approximately 48 hrs after treatment [71] . To clarify the role of P4 in the induction of CaBP-9k expression by E2 in rats, we treated immature rats with E2 in the absence or presence of P4. We found that P4 treatment reversed the E2-mediated induction of pituitary CaBP-9k expression [35] . These results were in agreement with the effect of E2 and P4 on uterine CaBP-9k expression. E2-induced increases in CaBP-9k expression were completely blocked by ICI 182,780, an ER antagonist [12, 74, 79] . Interestingly, the ER␣ pathway represents a major mechanism of induction of uterine CaBP-9k expression [74] . Uterine CaBP-9k expression during early pregnancy was reduced by P4. The E2-induced expression of CaBP-9k was also reversed by P4 treatment, which suggests that P4 is an antagonist of E2-mediated up-regulation of CaBP-9k [32] .
As described above, we have shown that the regulation of CaBP-9k by steroid hormones is similar in the pituitary and uterus [72] . In contrast to the mechanism of hormonal regulation of uterine CaBP-9k in rats, hormonal regulation of CaBP-9k in the reproductive tissues of mice is less well known [80, 81] [72] .
Transcriptional regulation of CaBP-9k
While it is well-established that CaBP-9k in the rat uterus is regulated by oestrogen, the putative ERE of CaBP-9k failed to bind to the ER in the mouse uterus [83] . Previously, we isolated several mouse genomic clones of CaBP-9k and used them to analyse CaBP-9k expression in the mouse uterus [45] . The [84] .
Uterine CaBP-9k may be involved in smooth muscle constriction at term and/or during implantation in the endometrium [72, 79, 86] . We recently reported that CaBP-9k expression is induced by endogenous and exogenous E2 in the pituitary glands of rats [72] 
